Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 425-431

  Gnanasekar, Munirathinam ^a   Thirugnanam, Sivasakthivel ^a   Ramaswamy, Kalyanasundaram ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

HMGB1; LNCaP; Prostate cancer; ShRNA

Indexed keywords

CASPASE 3; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; PLASMID VECTOR; SHORT HAIRPIN RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; CASPASE 3; CELL DIVISION; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HMGB1 PROTEIN; HUMANS; INVERTED REPEAT SEQUENCES; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 64549086420     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000166     Document Type: Article

References (36)

1. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81: 1-5, 2007.
2. Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195, 2002.
3. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H and Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570, 2000.
4. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH and Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660, 2003.
5. Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201, 2006.
6. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ and Yang H: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203: 1637-1642, 2006.
7. Takata K, Kitamura Y, Kakimura J, Shibagaki K, Tsuchiya D, Taniguchi T, Smith MA, Perry G and Shimohama S: Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem Biophys Res Commun 301: 699-703, 2003.
8. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, Lotze MT, Geller DA and Billiar TR: Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in non-parenchymal cells. J Immunol 175: 7661-7668, 2005.
9. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A and Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 13: 2836-2848, 2007.
10. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM and Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
11. Alexandrova EA and Beltchev BG: Differences between HMG1 proteins isolated from normal and tumour cells. Biochim Biophys Acta 915: 399-405, 1987.
12. Kuniyasu H, Chihara Y and Kondo H: Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 104: 722-727, 2003.
13. Kuniyasu H, Chihara Y, Kondo H, Ohmori H and Ukai R: Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep 10: 1863-1868, 2003.
14. Flohr AM, Rogalla P, Meiboom M, Borrmann L, Krohn M, Thode-Halle B and Bullerdiek J: Variation of HMGB1 expression in breast cancer. Anticancer Res 21: 3881-3885, 2001.
15. Takada M, Hirata K, Ajiki T, Suzuki Y and Kuroda Y: Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 51: 928-930, 2004.
16. Poser I, Golob M, Buettner R and Bosserhoff AK: Up-regulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998, 2003.
17. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y and Uemura H: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64: 92-100, 2005.
18. Lotze MT and De Marco RA: Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 4: 1405-1409, 2003.
19. Lotze MT: Cancer gene therapy: the power of negative thinking. Gene Ther 13: 191-193, 2006.
20. Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng 23: 17-34, 2006.
21. Putral LN, Gu W and McMillan NA: RNA interference for the treatment of cancer. Drug News Perspect 19: 317-324, 2006.
22. Paul CP, Good PD, Winer I and Engelke DR: Effective expression of small interfering RNA in human cells. Nat Biotechnol 20: 505-508, 2002.
23. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ and Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958, 2002.
24. Arnold JT, Le H, McFann KK and Blackman MR: Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 288: E573-E584, 2005.
25. Cui XS, Shen XH and Kim NH: High mobility group box 1 (HMGB1) is implicated in preimplantation embryo development in the mouse. Mol Reprod Dev 75: 1290-1299, 2008.
26. Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, Patrone M, Viani P, Sparatore B, Melloni E and Riboni L: HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 87: 23-33, 2008.
27. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H and Yasui W: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170, 2002.
28. Kuniyasu H, Chihara Y and Takahashi T: Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 10: 445-448, 2003.
29. Bantounas I, Phylactou LA and Uney JB: RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33: 545-557, 2004.
30. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S and Zornig M: HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 17: 1295-1297, 2003.
31. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA and Edwards DP: High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 18: 4471-4487, 1998.
32. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A and Gentile V: Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52: 964-972, 2007.
33. Stock D, Groome PA and Siemens DR: Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am 35: 117-130, 2008.
34. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, Beltrame M and Bianchi ME: New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 20: 4337-4340, 2001.
35. Stros M, Ozaki T, Bacikova A, Kageyama H and Nakagawara A: HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 277: 7157-7164, 2002.
36. Srikanth S and Kraft AS: Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 58: 834-839, 1998.